{
  "abstract": "Background\n\nObinutuzumab-based regimens are established frontline treatments for chronic lymphocytic leukemia (CLL), but infusion-related reactions (IRRs) and prolonged administration increase patient burden and outpatient chair occupancy. Evidence on shortened obinutuzumab infusion in CLL remains limited.Aims\n\nTo evaluate the safety, feasibility, and clinical outcomes of a 2-h obinutuzumab infusion protocol in treatment-naïve CLL.Methods\n\nThis retrospective single-center cohort study included 112 treatment-naïve patients receiving venetoclax-obinutuzumab (n = 72) or obinutuzumab-chlorambucil (n = 40). From cycle 1 day 8 onward, patients were managed according to either a shortened-infusion strategy (Short; n = 64) or a standard-duration strategy (Long; n = 48). The primary outcome was IRR incidence and severity; secondary outcomes included chair time, response rate, and progression-free survival.Results\n\nIRR rates did not differ significantly between the Short and Long groups (71.9% vs. 83.3%; odds ratio, 0.51; 95% confidence interval, 0.17-1.41; p = 0.18). Most IRRs occurred during the first infusion (87.4%), before implementation of the shortened protocol. Because cycle 1 day 1 and day 2 were administered using the same standard protocol in both groups, the safety comparison relevant to the shortened-infusion strategy begins at cycle 1 day 8; IRRs were infrequent from cycle 1 day 8 onward, and none occurred from cycle 1 day 15 onward, when eligible patients in the Short group were receiving the 2-h infusion. Grade 2 reactions predominated (91.6%); no Grade 4 IRRs occurred among the 112 patients included in the analysis. The shortened protocol saved 1.8 h per visit and 11.2 h per patient (42%). No apparent adverse signal in response or progression-free survival was observed.Conclusions\n\nIn frontline CLL care, a 2-h obinutuzumab infusion from cycle 1 day 8 was feasible, safe, and substantially reduced chair time, supporting its use to improve outpatient treatment efficiency.",
  "abstract_shown": true,
  "affiliations": [
    "4th Department of Internal Medicine - Hematology, University Hospital Hradec Králové, Hradec Králové, Czech Republic.",
    "Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic.",
    "Tissue Bank, University Hospital Hradec Králové, Hradec Králové, Czech Republic.",
    "Department of Clinical Pharmacy, Hospital Pharmacy, University Hospital Hradec Králové, Hradec Králové, Czech Republic."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Dominika Écsiová",
      "orcid": "0000-0002-6897-8756"
    },
    {
      "affs": [
        0,
        2
      ],
      "name": "Eva Vejražková",
      "orcid": "0000-0001-6281-8914"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Pavel Vodárek",
      "orcid": "0000-0002-8050-7594"
    },
    {
      "affs": [
        3
      ],
      "name": "Petra Rozsívalová",
      "orcid": "0000-0001-6114-3871"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Lukáš Smolej",
      "orcid": "0000-0002-4187-8595"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Pavel Žák",
      "orcid": "0000-0003-4465-5343"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Martin Šimkovič",
      "orcid": "0000-0003-0331-5334"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7b690j7bjjzp3.bib",
  "cited_by": 0,
  "doi": "10.1002/cam4.72409",
  "fulltext_url": "https://europepmc.org/articles/PMC13725073",
  "id": "7b690j7bjjzp3",
  "issns": [
    "2045-7634"
  ],
  "landing_url": "https://europepmc.org/article/MED/42968440",
  "language": "eng",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research Article"
    ],
    [
      "openalex",
      "2716|Chronic Lymphocytic Leukemia Research"
    ]
  ],
  "openalex": "W7225094397",
  "pdf_url": "https://europepmc.org/articles/PMC13725073?pdf=render",
  "pmcid": "PMC13725073",
  "pmid": "42968440",
  "published": "2026-11-01",
  "publisher": "Wiley",
  "ris": "https://research.draconitic.com/paper/7b690j7bjjzp3.ris",
  "sources": [
    {
      "first_seen": "2026-11-03T15:20:53Z",
      "native_id": "MED:42968440",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42968440"
    },
    {
      "first_seen": "2026-11-04T12:23:32Z",
      "native_id": "PMC13725073",
      "source": "pmc",
      "url": "https://doi.org/10.1002/cam4.72409"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2716|Chronic Lymphocytic Leukemia Research",
      "subfield": "human-genetics"
    }
  ],
  "title": "Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real-World Study.",
  "title_text": "Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real-World Study.",
  "type": "peer-reviewed",
  "updated_at": "2026-11-06T12:21:25Z",
  "url": "https://research.draconitic.com/paper/7b690j7bjjzp3",
  "venue": "Cancer medicine",
  "versions": []
}